Journal Article

Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion

Brain, Volume 149, Issue 11, November 2026, Pages 3681–3682, https://doi.org/10.1093/brain/awag308
Published:
21 October 2026
Article history
Received:
03 September 2026
Accepted:
03 September 2026
Corrected and typeset:
21 October 2026
Published:
21 October 2026

This scientific commentary refers to ‘Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis’, by Georgieva et al. (https://doi.org/10.1093/brain/awag171).

In contrast to many immune cells, which promote inflammation, regulatory T cells (Tregs) play a central role in preventing autoimmunity by suppressing immune activation and maintaining immune homeostasis. The discovery of these cells has provided profound insights into the control of autoimmunity, and the therapeutic manipulation of Tregs to prevent or treat autoimmune disease has become an important translational goal in immunology, with clear relevance to neurological disease.1

Tregs are a specialized subset of CD4+ T lymphocytes characterized by their ability to suppress autoimmunity. They express high levels of CD25, the alpha chain of the high affinity IL-2 receptor, and IL-2 promotes Treg survival, proliferation and immunosuppressive function.2 As such, Tregs are more sensitive to IL-2 signalling than conventional effector T cells. It is this differential response which has underpinned interest in the therapeutic use of IL-2 to selectively expand Tregs while avoiding activation of pathogenic effector cells. This strategy of preferential Treg expansion using low-dose IL-2 has shown promise in the treatment of autoimmune diseases such as systemic lupus erythematosus3 and iatrogenic immune disorders such as graft-versus-host disease.4

In this issue of Brain, Georgieva and colleagues5 explore the potential for low-dose IL-2-mediated Treg expansion to prevent the development of autoimmunity following the treatment of multiple sclerosis with alemtuzumab, a CD52-depleting monoclonal antibody. CD52 is expressed on mature lymphocytes, monocytes and dendritic cells, and alemtuzumab causes profound lymphocyte depletion.6 Alemtuzumab set a high bar for durable efficacy in the treatment of relapsing-remitting multiple sclerosis,6 often eliminating the need for continuous immunosuppression. However its widespread use has been limited by immunological side effects, in particular the ∼40% risk of developing secondary autoimmunity in the 5 years following treatment.7 The severity of this problem is reflected in European and US regulatory restrictions, which have limited the use of alemtuzumab in part because of these immunological safety concerns.

Alemtuzumab-associated autoimmunity can manifest in a number of ways. Most commonly, it causes autoimmune thyroid disease, but it can also lead to serious and potentially fatal complications such as immune thrombocytopenia, autoimmune encephalitis and Goodpasture’s syndrome.7 This autoimmunity occurs primarily during recovery from lymphopenia and represents an important example of how autoimmunity can arise in the context of immune reconstitution.8 A similar phenomenon is also observed following autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.9 Preventing these immunological complications has therefore become an important goal in the treatment of people with refractory inflammatory forms of multiple sclerosis.

Georgieva et al.5 hypothesized that boosting Treg function through the use of low dose IL-2 might represent a plausible strategy for preventing autoimmunity following alemtuzumab treatment.5 Their study combines preclinical in vitro assays of T cells following alemtuzumab treatment, a mouse model of alemtuzumab-mediated lymphocyte depletion, and an experimental medicine study to explore the feasibility of expanding Tregs using low-dose IL-2.

The authors first demonstrated the presence of Tregs in people with multiple sclerosis during the 6 months following alemtuzumab infusion. The gene expression profile of these Tregs suggested that they were responding to endogenous IL-2 signalling. However, to complicate matters, naïve CD4 T-effector cells also showed increased expression of the high affinity IL-2 receptor CD25, and enhanced responsiveness to IL-2 in vitro following alemtuzumab. This highlights the potential challenges of an IL-2-based Treg expansion strategy, since pro-inflammatory cells may also respond, reducing the selectivity of this approach for expansion of regulatory cells.

These findings raised a preclinical concern that IL-2 could inadvertently expand pro-inflammatory T cells in the pro-autoimmune environment that develops following alemtuzumab treatment. To understand this complex immunological scenario in vivo, the authors used a mouse model of alemtuzumab-mediated lymphodepletion. In mice expressing humanized CD52, alemtuzumab induced T cell lymphopenia, followed by an increase in the proportion of Tregs among CD4+ T cells. IL-2 treatment at a later time point (8 weeks) increased the Treg fraction, albeit by a relatively small amount. However, timing proved important: treatment at an earlier timepoint (2 weeks) did not lead to Treg expansion. Together these data suggest there may be a narrow therapeutic window during which IL-2 can preferentially expand regulatory T cell populations.

Informed by these preclinical observations and the success of low-dose IL-2 in other immune diseases, the authors proceeded to an experimental medicine study designed to evaluate whether low dose IL-2 could expand Treg populations in people with multiple sclerosis following treatment with alemtuzumab. Six people who had received alemtuzumab at least 6 months previously were recruited. IL-2 was found to be well tolerated and safe, consistent with safety profiles observed with prior therapeutic use. However, despite the strong biological rationale and encouraging preclinical data, the study did not achieve its primary end point of a significant percentage increase in Treg frequency.

The reasons for this failure of Treg expansion were considered in detail. For example, the findings could not be explained by elevated soluble IL-2 receptor alpha (sIL2RA), which can neutralize endogenous IL-2. This suggests the failure may lie in the cellular response to IL-2, for example Tregs may already have reached a ceiling of expansion, or they may be exhausted, as has been demonstrated following chronic exposure to inflammatory signals. Another possibility relates to intrinsic Treg dysfunction in multiple sclerosis. Functional defects in Tregs have been repeatedly observed in people with multiple sclerosis,10 raising the possibility of a more fundamental hyporesponsiveness of Tregs to IL-2 within the disease itself. This is a hypothesis which merits further evaluation and could provide insights into both the underlying disease and the immunological responses to high-efficacy therapies.

Lymphocyte depletion using monoclonal antibodies has a distinguished history in multiple sclerosis, both as a means of achieving durable, high efficacy disease control, and as a tool for providing insights into the nature of multiple sclerosis and autoimmunity.6 In totality, these findings suggest that low dose IL-2 is unlikely to represent an effective strategy to reduce alemtuzumab-associated autoimmunity. However, by revealing an unexpected hyporesponsiveness of Tregs in this complex immunological setting, this work provides further insight into the role of Tregs, with relevance to understanding both multiple sclerosis pathogenesis and the immunological response to lymphocyte depletion.

Funding

D.H. is a Wellcome Trust Senior Clinical Fellow and group leader in the UK Dementia Research Institute (principal funder: Medical Research Council).

Competing interests

The author reports no competing interests.

References

1

Naddaf
 
M
,
Gibney
 
E
.
Medicine Nobel goes to scientists who revealed secrets of immune system ‘regulation’
.
Nature
.
2025
;
646
:
521
–
522
.

2

Sakaguchi
 
S
,
Sakaguchi
 
N
,
Asano
 
M
,
Itoh
 
M
,
Toda
 
M
.
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
.
J Immunol
.
1995
;
155
:
1151
–
1164
.

3

He
 
J
,
Zhang
 
R
,
Shao
 
M
, et al.  
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial
.
Ann Rheum Dis
.
2020
;
79
:
141
–
149
.

4

Koreth
 
J
,
Matsuoka
 
K
,
Kim
 
HT
, et al.  
Interleukin-2 and regulatory T cells in graft-versus-host disease
.
N Engl J Med
.
2011
;
365
:
2055
–
2066
.

5

Georgieva
 
ZG
,
Howlett
 
SK
,
Rainbow
 
DB
, et al.  
Low-dose IL-2 fails to expand Tregs after alemtuzumab: Implications for impaired immune tolerance in multiple sclerosis
.
Brain
.
2026
;
149
:
4035
–
4051
.

6

CAMMS223 Trial Investigators
,
Coles
 
AJ
,
Compston
 
DA
, et al.  
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
.
N Engl J Med
.
2008
;
359
:
1786
–
1801
.

7

Cossburn
 
M
,
Pace
 
AA
,
Jones
 
J
, et al.  
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
.
Neurology
.
2011
;
77
:
573
–
579
.

8

Jones
 
JL
,
Thompson
 
SA
,
Loh
 
P
, et al.  
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
.
Proc Natl Acad Sci U S A
.
2013
;
110
:
20200
–
20205
.

9

Burt
 
RK
,
Muraro
 
PA
,
Farge
 
D
, et al.  
New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis
.
Bone Marrow Transplant
.
2021
;
56
:
1509
–
1517
.

10

Viglietta
 
V
,
Baecher-Allan
 
C
,
Weiner
 
HL
,
Hafler
 
DA
.
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis
.
J Exp Med
.
2004
;
199
:
971
–
979
.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period